Published in J Exp Med on July 01, 1973
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
Widespread natural occurrence of high titers of neutralizing antibodies to a specific class of endogenous mouse type-C virus. Proc Natl Acad Sci U S A (1974) 2.27
Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J Exp Med (1976) 2.11
Autogenous immunity to endogenous RNA tumor virus. Identification of antibody reactivity to select viral antigens. J Exp Med (1974) 2.10
Virus-specific neutralization by a soluble non-immunoglobulin factor found naturally in normal mouse sera. Proc Natl Acad Sci U S A (1975) 2.01
Identification of a cell-surface antigen selectively expressed on the natural killer cell. J Exp Med (1977) 1.97
Viral proteins expressed on the surface of murine leukemia cells. J Virol (1977) 1.60
Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice. J Virol (1976) 1.56
Identification of the Gross cell surface antigen associated with murine leukemia virus-infected cells. J Virol (1977) 1.54
Antibody response of mice to chemically induced tumors. Proc Natl Acad Sci U S A (1978) 1.41
Radiation leukemia in C57BL/6 mice. I. Lack of serological evidence for the role of endogenous ecotropic viruses in pathogenesis. J Exp Med (1976) 1.32
Radiation leukemia in C57BL/6 mice. II. Lack of ecotropic virus expression in the majority of lymphomas. J Exp Med (1976) 1.32
Lysis of leukemia cells by spleen cells of normal mice. Proc Natl Acad Sci U S A (1975) 1.20
Relationship of infectious murine leukemia virus and virus-related antigens in genetic crosses between AKR and the Fv-1 compatible strain C57L. J Exp Med (1976) 1.18
Characterization of the type and group specificities of the immune response in mice to murine leukemia viruses. J Virol (1976) 1.18
Autogenous immunity to endogenous RNA tumor virus: differential reactivities of immunoglobulins M and G to virus envelope antigens. J Virol (1974) 1.11
Interspecies brain antigen detected by naturally occurring mouse anti-brain autoantibody. Proc Natl Acad Sci U S A (1975) 1.09
Natural immunity in mice to the envelope glycoprotein of endogenous ecotropic type C viruses: neutralization of virus infectivity. J Virol (1977) 0.98
Genetic control of natural immunity to ecotropic mouse leukemia viruses: immune response genes. Infect Immun (1976) 0.95
Pathogenesis of arteritis of SL/Ni mice. Possible lytic effect of anti-gp70 antibodies on vascular smooth muscle cells. J Exp Med (1987) 0.94
Role of antibodies to murine leukemia virus p15E transmembrane protein in immunotherapy against AKR leukemia: a model for studies in human acquired immunodeficiency syndrome. Proc Natl Acad Sci U S A (1987) 0.90
Genetic control of natural immunity to ecotropic mouse leukemia viruses: production of endogenous immunogen. Infect Immun (1976) 0.89
Neonatal exposure to thymotropic gross murine leukemia virus induces virus-specific immunologic nonresponsiveness. J Exp Med (1990) 0.88
Synthesis of African swine fever (ASF) virus-specific antibodies in vitro in a porcine leucocyte system. Immunology (1987) 0.82
The humoral immune response of NIH Swiss and SWR/J mice to vaccination with formalinized AKR or Gross murine leukemia virus. Proc Natl Acad Sci U S A (1977) 0.82
Antibodies in human sera to oncorna virus-like proteins from normal or leukemia marrow cell cultures. J Exp Med (1976) 0.82
Sialylatin of glycoproteins of murine mammary tumor virus, murine leukemia virus, and Mason-Pfizer monkey virus. J Virol (1976) 0.82
Detection of polymorphism in BALB/c leukemia viruses with mouse antisera. J Virol (1979) 0.81
Leukemogenesis, immune responsiveness, and murine leukemia virus expression in congenic AKR/J mice differing at H-2. Infect Immun (1980) 0.80
Isolation and comparison of murine leukemia virus-related glycoproteins from AKR and New Zealand mice. J Virol (1977) 0.79
Expression of murine leukemia viruses in RFM mice with host versus graft disease after perinatal inoculation of (T6 X RFM)F1 lymphohemopoietic cells. Infect Immun (1983) 0.75
Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91
Induction of murine C-type viruses from clonal lines of virus-free BALB-3T3 cells. Science (1971) 6.71
Genetic mapping of a murine leukemia virus-inducing locus of AKR mice. Science (1972) 3.81
Occurrence of natural antibody to the G (gross) leukemia antigen in mice. Cancer Res (1966) 2.57
The antibody response of mice to murine leukemia virus in spontaneous infection: absence of classical immunologic tolerance (AKR mice-complement-fixing antibodies-lymphocytic choriomeningitis virus-immunofluorescence-glomerular deposits of antigen-antibody complexes). Proc Natl Acad Sci U S A (1972) 2.54
Radioimmune precipitation of group A arboviruses. J Immunol (1972) 1.71
Precipitation of radiolabeled poliovirus with specific antibody and antiglobulin. J Immunol (1962) 1.65
Radioimmunoassay procedure for rabies binding antibodies. J Immunol (1972) 1.49
Autogenous immunity to endogenous RNA tumor virus antigens in mice with a low natural incidence of lymphoma. Cancer Res (1972) 1.39
Wild-type Gross leukemia virus and heritable autoimmune disease of New Zealand mice. Am J Clin Pathol (1971) 1.09
NEUTRALIZATION IN VITRO OF MOUSE LEUKEMIA VIRUS BY SPECIFIC IMMUNE SERUM. IMPORTANCE OF VIRUS TITRATION. Proc Soc Exp Biol Med (1965) 0.92
Studies on the neutralization of the oncogenicity of Friend, Moloney, and Rauscher viruses. Cancer Res (1968) 0.91
Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature (1996) 6.17
JAK2 associates with the erythropoietin receptor and is tyrosine phosphorylated and activated following stimulation with erythropoietin. Cell (1993) 6.04
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Jak2 is essential for signaling through a variety of cytokine receptors. Cell (1998) 5.92
Requirement for Stat4 in interleukin-12-mediated responses of natural killer and T cells. Nature (1996) 5.45
Characterization and regulation of RB6-8C5 antigen expression on murine bone marrow cells. J Immunol (1991) 5.02
The developmental biochemistry of cottonseed embryogenesis and germination. 3. Regulation of the biosynthesis of enzymes utilized in germination. J Biol Chem (1972) 4.41
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-gamma signal transduction pathway. Nature (1993) 4.20
Mutations at the murine motheaten locus are within the hematopoietic cell protein-tyrosine phosphatase (Hcph) gene. Cell (1993) 4.06
Hormonal regulation of translation inhibition requiring RNA synthesis. Biochem Biophys Res Commun (1970) 4.01
Procedures for the purification of interleukin 3 to homogeneity. J Immunol (1982) 3.96
Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sci U S A (1987) 3.92
The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J (1999) 3.77
Exercise intolerance due to mutations in the cytochrome b gene of mitochondrial DNA. N Engl J Med (1999) 3.76
Retroviral activation of a novel gene encoding a zinc finger protein in IL-3-dependent myeloid leukemia cell lines. Cell (1988) 3.75
Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell (1993) 3.54
Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity (1999) 3.53
Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. Lancet (2001) 3.39
Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lymphoid and myeloid cells. Nature (1994) 3.36
Cutting edge: Stat6-dependent substrate depletion regulates nitric oxide production. J Immunol (2001) 3.25
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25
SOCS1 deficiency causes a lymphocyte-dependent perinatal lethality. Cell (1999) 3.15
Phospholipase Cgamma2 is essential in the functions of B cell and several Fc receptors. Immunity (2000) 3.06
Defective lymphoid development in mice lacking Jak3. Science (1995) 3.04
Structure of the murine Jak2 protein-tyrosine kinase and its role in interleukin 3 signal transduction. Proc Natl Acad Sci U S A (1993) 2.88
Amino- and carboxyl-terminal amino acid sequences of proteins coded by gag gene of murine leukemia virus. Proc Natl Acad Sci U S A (1978) 2.87
Voltage sensor charge loss accounts for most cases of hypokalemic periodic paralysis. Neurology (2008) 2.87
Interleukin 3: A differentiation and growth factor for the mouse mast cell that contains chondroitin sulfate E proteoglycan. J Immunol (1984) 2.85
Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits. Science (1994) 2.65
Neoplastic transformation of mast cells by Abelson-MuLV: abrogation of IL-3 dependence by a nonautocrine mechanism. Cell (1985) 2.59
JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol (1994) 2.55
Inhibition of Th1 differentiation by IL-6 is mediated by SOCS1. Immunity (2000) 2.54
Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol (1997) 2.51
Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol (1993) 2.50
B cell stimulatory factor-1/interleukin-4 mRNA is expressed by normal and transformed mast cells. Cell (1987) 2.44
Truncation of the c-myb gene by a retroviral integration in an interleukin 3-dependent myeloid leukemia cell line. Proc Natl Acad Sci U S A (1986) 2.43
Protein tyrosine phosphatase containing SH2 domains: characterization, preferential expression in hematopoietic cells, and localization to human chromosome 12p12-p13. Mol Cell Biol (1992) 2.41
Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell (2000) 2.41
Constitutive production of a unique lymphokine (IL 3) by the WEHI-3 cell line. J Immunol (1982) 2.22
Contenders in FasL/TNF death signaling. Cell (1995) 2.21
Localization of 125I-labeled antigen in germinal centers of mouse spleen: histologic and ultrastructural autoradiographic studies of the secondary immune reaction. J Immunol (1968) 2.21
SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell (1999) 2.19
The primary periodic paralyses: diagnosis, pathogenesis and treatment. Brain (2005) 2.17
Serological and virological analysis of NIH (NIH X AKR) mice: evidence for three AKR murine leukemia virus loci. Virology (1978) 2.13
Interleukin-3 signals through multiple isoforms of Stat5. EMBO J (1995) 2.12
Interferon-induced nuclear signalling by Jak protein tyrosine kinases. Nature (1993) 2.10
Autogenous immunity to endogenous RNA tumor virus. Identification of antibody reactivity to select viral antigens. J Exp Med (1974) 2.10
Regulation of T cell differentiation: in vitro induction of 20 alpha-hydroxysteroid dehydrogenase in splenic lymphocytes from athymic mice by a unique lymphokine. J Immunol (1981) 2.01
Virus-specific neutralization by a soluble non-immunoglobulin factor found naturally in normal mouse sera. Proc Natl Acad Sci U S A (1975) 2.01
Stat4, a novel gamma interferon activation site-binding protein expressed in early myeloid differentiation. Mol Cell Biol (1994) 1.98
Neurological channelopathies. Postgrad Med J (2005) 1.98
Identification of a common ecotropic viral integration site, Evi-1, in the DNA of AKXD murine myeloid tumors. Mol Cell Biol (1988) 1.95
Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain (2007) 1.91
Activation of EVI1 gene expression in human acute myelogenous leukemias by translocations spanning 300-400 kilobases on chromosome band 3q26. Proc Natl Acad Sci U S A (1992) 1.90
Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission. Proc Natl Acad Sci U S A (1995) 1.89
Permissive role of interleukin 3 (IL-3) in proliferation and differentiation of multipotential hemopoietic progenitors in culture. J Cell Physiol (1985) 1.87
Hematopoietic cell phosphatase associates with the interleukin-3 (IL-3) receptor beta chain and down-regulates IL-3-induced tyrosine phosphorylation and mitogenesis. Mol Cell Biol (1993) 1.86
The ultrastructure of antigen localization and viruslike particles in mouse spleen germinal centers. Exp Mol Pathol (1968) 1.86
Erythropoietin induces activation of Stat5 through association with specific tyrosines on the receptor that are not required for a mitogenic response. Mol Cell Biol (1996) 1.86
Hematopoietic cells express two forms of lyn kinase differing by 21 amino acids in the amino terminus. Mol Cell Biol (1991) 1.84
Association of hematopoietic cell phosphatase with c-Kit after stimulation with c-Kit ligand. Mol Cell Biol (1993) 1.84
A novel mutation in the human voltage-gated potassium channel gene (Kv1.1) associates with episodic ataxia type 1 and sometimes with partial epilepsy. Brain (1999) 1.84
Localization of Evi-2 to chromosome 11: linkage to other proto-oncogene and growth factor loci using interspecific backcross mice. Oncogene Res (1988) 1.82
Induction of tyrosine phosphorylation by the erythropoietin receptor correlates with mitogenesis. Mol Cell Biol (1991) 1.81
Establishment of continuous cultures of thy1.2+, Lyt1+, 2-T cells with purified interleukin 3. Cell (1981) 1.80
Genetic linkage of C3H/HeJ and BALB/c endogenous ecotropic C-type viruses to phosphoglucomutase-1 on chromosome 5. Science (1979) 1.79
Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proc Natl Acad Sci U S A (1994) 1.78
Electron microscopic autoradiography of germinal center cells in mouse spleen. J Cell Biol (1965) 1.78
Abrogation of IL-3 and IL-2 dependence by recombinant murine retroviruses expressing v-myc oncogenes. Nature (1985) 1.77
Biological and serological characterization of radiation leukemia virus. Proc Natl Acad Sci U S A (1976) 1.77
Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. Blood (2000) 1.74
Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130. Proc Natl Acad Sci U S A (1994) 1.74
Phosphorylation and activation of the DNA binding activity of purified Stat1 by the Janus protein-tyrosine kinases and the epidermal growth factor receptor. J Biol Chem (1995) 1.72
Naturally occurring dominant negative variants of Stat5. Mol Cell Biol (1996) 1.71
Kinase-negative mutants of JAK1 can sustain interferon-gamma-inducible gene expression but not an antiviral state. EMBO J (1996) 1.71
International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) (2003) 1.71
Serological characterization of B-tropic viruses of C57BL mice: possible origin by recombination of endogenous N-tropic and xenotropic viruses. Proc Natl Acad Sci U S A (1978) 1.70
Phenotypic characteristics of cell lines requiring interleukin 3 for growth. J Immunol (1982) 1.67
The distal region and receptor tyrosines of the Epo receptor are non-essential for in vivo erythropoiesis. EMBO J (2001) 1.67
The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment. Brain (2009) 1.65
Clinical, genetic, and expression studies of mutations in the potassium channel gene KCNA1 reveal new phenotypic variability. Ann Neurol (2000) 1.64
A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. Mol Cell Biol (1997) 1.62
Inactivation of erythropoietin receptor function by point mutations in a region having homology with other cytokine receptors. Mol Cell Biol (1993) 1.62
Structure, tissue-specific expression, and transforming activity of the mouse met protooncogene. Cell Growth Differ (1990) 1.62
Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. Genes Dev (2000) 1.61
Expression of the Evi-1 zinc finger gene in 32Dc13 myeloid cells blocks granulocytic differentiation in response to granulocyte colony-stimulating factor. Mol Cell Biol (1992) 1.61
Retroviral insertions 90 kilobases proximal to the Evi-1 myeloid transforming gene activate transcription from the normal promoter. Mol Cell Biol (1991) 1.61
Correlation of cell-surface phenotype with the establishment of interleukin 3-dependent cell lines from wild-mouse murine leukemia virus-induced neoplasms. Proc Natl Acad Sci U S A (1985) 1.61
Nongenetic factors influence severity of episodic ataxia type 1 in monozygotic twins. Neurology (2010) 1.59
Expression of a novel form of Tec kinase in hematopoietic cells and mapping of the gene to chromosome 5 near Kit. Oncogene (1993) 1.58
raf family serine/threonine protein kinases in mitogen signal transduction. Cold Spring Harb Symp Quant Biol (1988) 1.57
Purification and serological characterization of the major envelope glycoprotein from AKR murine leukemia virus and its reactivity with autogenous immune sera from mice. J Virol (1976) 1.56
Restoration of lymphocyte function in Janus kinase 3-deficient mice by retroviral-mediated gene transfer. Nat Med (1998) 1.54
Effects of polyadenylic acids on functions of murine RNA tumor viruses. J Virol (1973) 1.53
Unique expression of the human Evi-1 gene in an endometrial carcinoma cell line: sequence of cDNAs and structure of alternatively spliced transcripts. Oncogene (1990) 1.53
Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet (1993) 1.53
Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients. Lancet (1993) 1.51